Introduction {#s1}
============

Hematopoietic stem cell transplantation (HSCT) is currently used as a curative treatment for a wide range of diseases, including malignancies such as leukaemia and lymphomas and non-malignant diseases such as metabolic and haematological disorders. Conditioning regimens - either a combination of cytostatics or cytostatics together with radiotherapy - are designed to prepare the patient to receive donor stem cells. Cytostatics are administered in order to eliminate malignant cells, provide free space for the donor cells and suppress the immune system in order to prevent graft rejection [@pone.0086619-Burt1].

Cyclophosphamide (Cy) is an alkylating agent widely used as a part of the conditioning regimen prior to HSCT and for the treatment of haematological malignancies and solid tumours. Cy is used either in combination with other cytostatics or with total body irradiation (TBI) [@pone.0086619-Reynolds1]. It acts on DNA by attaching an alkyl group to the guanine base of DNA at the number 7 nitrogen atom of the imidazole ring and leads to guanine-adenine intra-strand cross-linking. This damage to the DNA strand can trigger apoptosis when the cellular machinery fails to repair it.

Cy is also a potent immunosuppressive agent i.e. it is capable of attenuating both humoral and cell-mediated immune responses [@pone.0086619-Daleboudt1]. Due to these immunosuppressive effects, Cy is used in the treatment of several autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosus [@pone.0086619-Binotto1].

Cy is a prodrug that is metabolized by cytochrome P450 to its main active metabolite, 4-hydroxycyclophosphamide (4-OH-Cy), which comprises about 90% of the total Cy dose [@pone.0086619-Sladek1]. 4-OH-Cy is subsequently converted to phosphoramide mustard and acrolein, which is nephrotoxic. An alternative pathway of Cy transformation is N-dechloroethylation. Moreover, Cy is partly metabolized to the inactive metabolite 2-dechloroethyl-Cy and to chloroacetaldehyde, which is neurotoxic [@pone.0086619-Cho1]--[@pone.0086619-Ren1].

Studies on Cy kinetics have shown a high inter-individual variation in elimination half-life and clearance [@pone.0086619-Cho1], [@pone.0086619-Xie1]. This variation may be explained by polymorphisms in CYP2B6, the main enzyme responsible for the conversion of Cy to its active form [@pone.0086619-Klein1]--[@pone.0086619-Tsuchiya1].

Several studies have investigated the clinical efficacy of Cy alone or in combination with other cytostatics or radiotherapy [@pone.0086619-Reynolds1], [@pone.0086619-Eroglu1]. However, the contribution of Cy to the outcome of HSCT and, more importantly, the mechanisms by which Cy exerts its effect on immune cells has not yet been addressed.

In the past decade, the advent of DNA microarray technology together with the availability of the complete nucleotide sequence of the human genome have allowed elucidation of the molecular mechanisms in several diseases [@pone.0086619-deJonge1], [@pone.0086619-Mills1] or treatment regimens [@pone.0086619-Khokher1], [@pone.0086619-Rimsza1]. In order to understand the effect of high dose cyclophosphamide on different genes, we employed the DNA microarray to investigate the gene expression profile in peripheral mononuclear cells of patients suffering from haematological malignancies and undergoing conditioning regimen consisting of Cy followed by TBI. We followed the gene profile pre-, during and after treatment.

Materials and Methods {#s2}
=====================

Patients and Treatment {#s2a}
----------------------

Eleven patients were enrolled in this study. The patients were admitted at the Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital-Huddinge. The study was approved by the ethical committee of Karolinska Institutet (616/03) and written informed consent was obtained from the patients or, in case of paediatric patients, their parents. Twelve samples from healthy donors, who had given their written consent, were run concomitantly as negative controls. The ethics committee approved the consent procedure. Six of these patients were diagnosed with acute lymphocytic leukaemia (ALL), two with acute myeloid leukaemia (AML), two with T-cell lymphoma and one with chronic lymphocytic leukaemia (CLL). Patient characteristics are presented in [Table 1](#pone-0086619-t001){ref-type="table"}.

10.1371/journal.pone.0086619.t001

###### Patient characteristics.

![](pone.0086619.t001){#pone-0086619-t001-1}

  Patient Code    Age (years)      Diagnosis         Conditioning regimen       Stem cells source   Donor     CD 34 dose/Kg      Disease status at HSCT   Acute GVHD                    Outcome                          Cause of death
  -------------- ------------- ----------------- ----------------------------- ------------------- ------- -------------------- ------------------------ ------------ -------------------------------------------- ---------------------------
  **P 1**             57             B-CLL        CP+fTBI (6 Gy)+ Alemtuzumab         PBSC           Sib        14.7×10^6^            Transformed          Grade II    [†](#nt102){ref-type="table-fn"} 10 months            Relapse
  **P 2**             38        T cell lymphoma             CP+fTBI                    BM            Sib        2.9×10^8^                  PR              Grade II    [†](#nt102){ref-type="table-fn"} 19 months            Relapse
  **P 3**             31              AML                 CP+fTBI+ATG                  BM            MUD         2×10^6^                  CR2              Grade II    [†](#nt102){ref-type="table-fn"} 6 months            Pneumonia
  **P 4**             10             T-ALL                CP+fTBI+ATG                  BM            Sib        6.48×10^8^                CR1              Grade I     [†](#nt102){ref-type="table-fn"} 12 months            Relapse
  **P 5**             26           Pre B-All              CP+fTBI+ATG                 PBSC           MUD        13.5×10^6^                CR2              Grade II    [†](#nt102){ref-type="table-fn"} 35 months            Relapse
  **P 6**             19              ALL                 CP+fTBI+ATG                 PBSC           MUD        13.5×10^6^                CR3                 No       [†](#nt102){ref-type="table-fn"} 9 months       Relapse & pneumonia
  **P 7**             51              AML                 CP+fTBI+ATG                 PBSC           Sib        10.6×10^6^             Refractory          Grade I                  Alive 7.5 years                            --
  **P 8**             25           Pre B-ALL              CP+fTBI+ATG                 PBSC           Sib        7.3×10^6^                 CR2              Grade II                 Alive 7.5 years                            --
  **P 9**             14             T-ALL                CP+fTBI+ATG                 PBSC           MUD        19.9×10^6^                CR2              Grade II                 Alive 7.2 years                            --
  **P 10**            41        T cell lymphoma           CP+fTBI+ATG                 PBSC           MUD        9.3×10^6^               Relapse            Grade I      [†](#nt102){ref-type="table-fn"} 51 days    Invasive fungal infection
  **P 11**            26             T-ALL                CP+fTBI+ATG                 DUCB          DUCB    0.5×10^5^0.2×10^5^            CR2              Grade I     [†](#nt102){ref-type="table-fn"} 11 months            Relapse

**Abbreviations:** GVHD, graft versus host disease; P, patient; CLL, chronic lymphoblastic leukaemia; AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; CP, cyclophosphamide; fTBI, fractionated total body irradiation; ATG, antithymocyte globulin; PBSC, peripheral blood stem cells; BM, bone marrow; Sib, HLA-identical sibling; MUD, matched unrelated donor; DUCB, Double umbilical cord blood; CR, complete remission; PR, partial remission;

survival.

All the patients received an i.v. infusion of Cy 60 mg/kg/day once daily for two days followed by fractionated TBI 3 Gy (gray) x 4, except the first patient who only received 6 Gy in total. Blood samples were collected from each patient before the start of Cy infusion, 6 h after the first dose of Cy, before and 6 h after the second dose of Cy. Samples have been numbered with the patient's number followed by −1, −2, −3 and −4.

All patients with unrelated donors received antithymocyte globulin (ATG, Thymoglobulin, Genzyme, Cambridge, MA, USA), at a total dose of 6 mg/kg given at day −4--−1 during the conditioning treatment. The single exception was the first patient, who had a sibling donor and received Alemtuzumab 30 mg × 1 due to CD52 expression of the leukaemia.

GVHD Prophylaxis {#s2b}
----------------

GVHD prophylaxis consisted of cyclosporine (CsA) in combination with four doses of methotrexate (MTX) [@pone.0086619-Ringden1]. During the first month, blood CsA levels were kept at 100 ng/mL when a sibling donor was used, and at 200--300 ng/mL when an unrelated donor was used. In the absence of GVHD, CsA was discontinued after three to four months for patients with sibling donors and six months for patients with MUD.

Diagnosis and Treatment of GVHD {#s2c}
-------------------------------

Acute and chronic GVHD were diagnosed on the basis of clinical symptoms and/or biopsies (skin, liver, gastrointestinal tract, or oral mucosa) according to standard criteria [@pone.0086619-Przepiorka1]. The patients were treated for grade I acute GVHD with prednisolone, starting at a dosage of 2 mg/kg/day, which was successively lowered after the initial response. Chronic GVHD was initially treated with CsA and steroids. In most cases, daily prednisone at 1 mg/kg per day and daily CsA at 10 mg/kg per day were used [@pone.0086619-Remberger1].

Blood Sampling and RNA Extraction {#s2d}
---------------------------------

Blood samples for RNA extraction were collected in PAXgene tubes (BD, Stockholm, Sweden). RNA was extracted using QuickPrep Total RNA Extraction Kit (GE Life Sciences, Uppsala, Sweden) according to the manufacturer's instructions and then quantified by measuring the absorbance at 260 and 280 nm. All samples were stored at −180°C.

Gene Expression Assay and Analysis {#s2e}
----------------------------------

Purified mRNA was subjected to analysis of global gene expression by using NimbleGen microarrays (Roche Diagnostics Scandinavia, Bromma, Sweden). Data were analyzed using GeneSpring GX (Agilent, CA, USA). The expression data were normalized using quantile normalization and the gene expression data were generated using the Robust Multichip Average algorithm. Significant differences in gene expression were determined by ANOVA. The selection threshold of a false discovery rate (FDR) was \<5% and the fold change in the SAM output result was \>2. The complete data (ID no. 20051907) is available via the GEO database with the accession number "GSE51907".

Pathway identification and reporting was performed using IPA software (Ingenuity, Qiagen, CA, USA) and Kyoto Encyclopaedia of Genes and Genomes software (KEGG) (Kyoto University Bioinformatics Centre, Japan).

cDNA Synthesis and Real Time PCR (qRTPCR) {#s2f}
-----------------------------------------

Two micrograms of RNA were reversed transcribed to complementary DNA (cDNA) using the TaqMan Reverse Transcriptase cDNA Kit (Applied Biosystems, Roche, NJ, USA) and then stored at −80°C. TaqMan gene expression assay (Applied Biosystems, Stockholm, Sweden) was performed by means of the FAM dye labelling system according to the manufacturer's instructions. The assay was performed for the selected genes that showed significantly high expression, ANGPTL1 and c-JUN (assay IDs; Hs00559786_m1 and Hs01103582_s1, respectively) and GAPDH (assay ID; Hs02758991_g1) as a housekeeping gene (Applied Biosystems, Stockholm, Sweden). Real time PCR (qRTPCR) reactions were performed in a 384-well plate thermal cycler ABI 7900 (Applied Biosystems, Stockholm, Sweden) in a total volume of 10 µL and results were normalized against the housekeeping gene GAPDH. Twelve samples from healthy donors were run concomitantly as negative controls.

Results {#s3}
=======

Outcome of HSCT after Conditioning with Cy and TBI {#s3a}
--------------------------------------------------

As shown in [Table 1](#pone-0086619-t001){ref-type="table"}, all patients received allogeneic HSCT either from their siblings (5 patients) or from MHC-matched unrelated donors (MUD) (5 patients) after conditioning with Cy and TBI. Stem cells from peripheral blood (PBSC) were given to 7 patients, and 3 patients received bone marrow (BM). One patient received a double umbilical cord blood (DUCB) transfusion.

Most of the patients were in remission at the time of transplantation (8/11, 72.7%). Acute GVHD, either grade I or grade II, was reported in 10 patients (90.9%). The overall survival was 27.3% (3/11 patients) and relapse was the main cause of death in most of the patients (6/8, 75%).

Identification of Differentially Expressed Genes and Gene Clusters Related to Cy Treatment {#s3b}
------------------------------------------------------------------------------------------

We assessed the overall patterns of gene expression in 11 patients with haematological malignancies treated with Cy. The assessment was performed utilizing a hierarchical clustering analysis of the signal ratios of all arrays. The heat map representing array clustering based on normalized probe intensity showed a high inter-individual variation, as expected ([Figure 1A](#pone-0086619-g001){ref-type="fig"}). In the present study we observed variation in several thousands of genes during and after Cy treatment. However, after fold-change filtering (at least 2-fold compared to time 0, i.e. before treatment), differential expression of a group of 299 genes was identified as being specific for Cy treatment. By subjecting these genes to hierarchical clustering analysis, we were able to identify 4 clusters of up- and down-regulated genes which matched the chronological cascade of gene expression by cyclophosphamide treatment: highly down-regulated genes (cluster 1), highly up-regulated genes (cluster 2), early up-regulated but later normalized genes (cluster 3) and moderately up-regulated genes (cluster 4) ([Figure 1B](#pone-0086619-g001){ref-type="fig"}).

![Heat map of patient gene expression during Cy treatment.\
Genes expression for genes specific for Cy before and though the treatment (A). Differential expression of a group of 299 genes was identified as being specific for Cy treatment. After subjecting these genes to hierarchical clustering analysis, 4 clusters of up- and down-regulated genes were identified as: highly down-regulated genes (cluster 1), highly up-regulated genes (cluster 2), early up-regulated but later normalized genes (cluster 3) and moderately up-regulated genes (cluster 4) as seen in B.](pone.0086619.g001){#pone-0086619-g001}

### Highly down-regulated genes (cluster 1) {#s3b1}

The first cluster represents genes that were relatively up-regulated in all patients prior to cyclophosphamide treatment; however, this cluster was down-regulated at 6 h post administration followed by a pronounced decrease in expression at 30 h (i.e. 6 h after the second dose; [Fig. 2A](#pone-0086619-g002){ref-type="fig"}). This cluster possessed the highest number of genes (139 genes, [Table 2](#pone-0086619-t002){ref-type="table"}). The majority of these genes belonged to the immune system and its functions ([Table 3](#pone-0086619-t003){ref-type="table"}). Moreover, further analysis of biological pathways related to these genes showed that a majority of immune- (e.g. T cell receptor signalling, natural killer cell mediated cytotoxicity and graft rejection), autoimmune- (e.g. autoimmune thyroid disease pathway, type 1 diabetes mellitus and rheumatoid arthritis) and inflammation- (e.g., GVHD and NF-kB signalling) related processes were down-regulated by the Cy treatment ([Figure 3A](#pone-0086619-g003){ref-type="fig"}).

![Gene clusters in relation to Cy treatment.\
The expression of Cy treatment specific genes at 6(30 h) was normalized to the pre-treatment and divided to the following clusters: Cluster 1 showed highly down-regulated genes throughout the treatment (A). Cluster 2 showed highly up-regulated genes throughout the treatment (B). Cluster 3 showed early up-regulated but later normalized genes (C). Cluster 4 showed moderately up-regulated genes (D).](pone.0086619.g002){#pone-0086619-g002}

![The pathways related to each cluster and number of genes involved in each cluster.\
Cluster 1 for highly down-regulated genes throughout the treatment (A) included the highest number of genes. The majority of these genes belonged to the immune system and its functions. Cluster 2 for highly up-regulated genes throughout the treatment (B), the majority of these genes are involved in 3 important biological pathways involving cytokine-cytokine receptor interaction, transcriptional misregulation in cancer and hematopoietic cell lineage. Cluster 3 showed early up-regulated but later normalized genes (C), these genes were more related to biological pathways including Jak-STAT and MAPK signalling. Cluster 4 showed moderately up-regulated genes (D), the pathway analysis demonstrated that several pathways including cytokine-cytokine receptor interaction, Jak-STAT signalling pathway and TGF-beta signalling are involved.](pone.0086619.g003){#pone-0086619-g003}

10.1371/journal.pone.0086619.t002

###### All genes specific for CP treatment arranged in 4 clusters.
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  Cluster 1    Cluster 2    Cluster 3   Cluster 4                                                                                                    
  ----------- ------------ ----------- ----------- -------- ---------- ----------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  TNIK           DYRK2       TMEM116      IL5RA     PTPN4      MRAS     RASGEF1A     FKBP5     SEC14L2    ST8SIA2      TRIO      MCEMP1     AP3B2     ANGPTL7
  HEG1         ST6GALNAC6     ITGA4       CD3D       RORA     TKTL1       FKBP5       FLT3     PSORS1C2   ST8SIA5      HFE       MYO10        KL       ZNF708
  STK39         HLA-DQA1      TNIK        CD3E       XCL1      GNLY       VSIG4      CD163      KLK13      OR12D2     ZNF396     USP37     HIST1H1T    ZNF500
  RALGDS          MCM7       PTPLAD1      IL2RB      XCL2     GPR171    CRISPLD2      ASPH      CHST1      NR2F2      SEC24D     HYLS1      H3F3B      SAMSN1
  AES             IL32        XPO5        ITGA4      UNG      OLFM1     HIST1H2BC    IL1R2      WFDC1      KCNK10     RNF175     SLC3A1     ABCA1      ITPKC
  CD244          MAGEH1      SEPT11       GATA3     RUVBL1   KIR2DS1     ECHDC3      PFKFB2     ADRA2A     WFDC1     FLJ36031    BRCA2       MCAM     MGC11332
  GSDML           SPN         MASA       ABLIM1     PEX11A     TNIK       GRB10      VSIG4      DYRK3      SPRY4      CCDC62       F8       HS2ST1     ZNF558
  KLRC3           LCK        KIR2DL1      TARP       DOK2     NUP205      APBB2     ADAMTS2      THY1     FLJ39155    TREX2       LPL       SOCS5      DNAJB7
  GSDML          FCER1A       XCL2        AKAP2     MFHAS1    POLR1A      CD177      DAAM2       FBN1      CPLX4     FLJ46419     HPGD      SYCP2      ZNF396
  POLR1B          NKG7        CTLA4       SSBP3      DDX1    ZNFN1A2      BCAT1      THEDC1     SPATS1      NNAT      EDA2R     FLJ44796   ITGB3BP     ZNF718
  PCNT           PRKACB       XCL1        IL32       PRF1     KLF12       KCNE1       ASPH      OR10J1     PTHLH     FLJ21963    ZNF613     CPEB3      MCEMP1
  MRPL1           CD96        CCR4         LAT      CSF1R     CD244      PFKFB2      CD177       GP2      ZCCHC13    IL13RA1     CNGA4      KIF1B      MFSD4
  PRKACB         SH2D1B      PRSS21       SAMD3     GPR15      ABI3      IL18R1     ADAMTS2     TRPV4       DUB3     ITGB3BP      ARL1      PPARG     TMEM119
  FLJ20701        GNLY       GPR162       CTSW       LCK      TEX10       KCNE1     RASGEF1A     TBX5     HSD17B2    ARHGAP29    BMPR2      UBE2J1     CCDC62
  ABLIM1         CDCA7        IGHG1      CX3CR1      MAF     FLJ20701      CA4       APBB2      OR56A1      DMP1      KLHL8       KLF9       CNR1     FLJ43806
  GZMB          ZNFN1A2       KLRC2       CD38       CCR4     HEATR1      GRB10     MGC34646    NTRK2       MALL       DC36      FOXC1      IL1RL1    FLJ44313
  ZNFN1A2        MRPL1        CD28        FKBP4     SMAD7     GSDML      THEDC1      CD163       DRP2                 RPS27L     INHBB      PRPF39     TMED8
  RASGRP1         CBLB       CYSLTR2      GZMK       MCM4     EEFSEC       ADM        ASPH                           CRISPLD2    KCNMA1     FEM1C       HPGD
  PPIE           KCNA3        MYBL1        HDC       GZMA     DDX31      ALOX15B     IL1R2                           SLC10A1    TACSTD1     ACVR1B     STRA13
  CETN3          MLLT3        LPAL2       NID1       GNLY     LYNX1       CA12       IL18R1                            CNR1      TIMP4      SRGAP1      HPGD
  NUP37         MTAC2D1      NFATC2      PRKACB      MLC1    PIK3C2B      TPST1                                        FEZ2      IL1RL1     LRRN1     FLJ42562
  NCALD          INADL        IL5RA        LCK      MYBL1    KIR2DS1                                                 TMEM119     ACSL3      GCN5L2     CNGA4
  TMEM116         CBLB      FLJ46020                                                                                  SYCP2       FMN1               

10.1371/journal.pone.0086619.t003

###### Pathways reported in each cluster and genes involved in each of them.

![](pone.0086619.t003){#pone-0086619-t003-3}

  Cluster                          Pathways                                         Genes
  --------------- ------------------------------------------- --------------------------------------------------
  **Cluster 1**           T cell receptor signalling           CTLA4, CD3ε, CD3δ, CD28, Lck, LAT, RasGRP1, NFAT
                   Natural killer cell mediated cytotoxicity           Lck, LAT, NFAT, 2B4, GZMB, PRF1
                               HTLV-1 infection                           CD3, IL2R, NFAT, Ras, Lck
                    Cytokine-cytokine receptor interaction            CX3CR1, CCR4, IL5RA, IL2RB, CSF1R
                           Type 1 diabetes mellitus                     INS, MHC-II, CD28, PRF1, GZMB
                          Autoimmune thyroid disease                       CTLA4, CD28, PRF1, GZMB
                          Hematopoietic cell lineage                       CD3, CD115, IL5RA, CD49
                            Cell adhesion molecules                        CD28, CTLA4, SPN, ITGA4
                                    Measles                                    CD3, CD28, IL2R
                              Allograft rejection                              CD28, PRF1, GZMB
                              PI3K-Akt signalling                           RTK, Cytokine R, ITG A
                    Transcriptional misregulation in cancer                    LMO2, PAX3, PAX7
                           Graft-versus-host disease                           CD28, PRF1, GZMB
                                 RNA transport                               Exp5, Nup37, Nup205
                           Fc epsilon RI signalling                              FcεRIα, LAT
                              Pathways in cancer                                Ra1GDS, MCSFR
                                DNA replication                                   Mcm4, Mcm7
                                  Cell cycle                                      Mcm4, Mcm7
                                MAPK signalling                                  RasGRP1, Ras
                             Rheumatoid arthritis                                CD28, CTLA4
                            NF- Kappa B signalling                                 Lck, LAT
  **Cluster 2**     Cytokine-cytokine receptor interaction                   FLT3, IL1R2, IL18R1
                          Hematopoietic cell lineage                             CD135, CD121
                            Acute myeloid leukaemia                                  AML1
  **Cluster 3**                 MAPK signalling                                     TrkA/B
                         Steroid hormone biosynthesis                          17beta-estradiol
                            Gastric acid secretion                                   KCN
                                  Alcoholism                                         TrkB
                     Leukocyte transendothelial migration                            Thyl
                    Neuroactive ligand-receptor interaction                          ADR
                            Neurotrophin signalling                                  TrkB
                              Jak-STAT signalling                                  Sprouty
                            Ovarian steroidogenesis                                17β-HSD
                                MAPK signalling                                     TrkA/B
  **Cluster 4**     Cytokine-cytokine receptor interaction              IL13RA1, XEDAR, ACVR1B, BMPR2
                              Jak-STAT signalling                              CytokineR, SOCS
                              TGF-beta signalling                             BMPRII, ActivinR1
                       Fc gamma R-mediated phagocytosis                            Myosin X
                      Complement and coagulation cascade                   coagulation factor VIII

### Highly up-regulated genes (cluster 2) {#s3b2}

In contrast to cluster 1, this group of genes exhibited a constant and high up-regulation in response to Cy treatment ([Fig. 2B](#pone-0086619-g002){ref-type="fig"}). In this cluster, 41 up-regulated genes were identified ([Table 2](#pone-0086619-t002){ref-type="table"}). The majority of these genes are involved in 3 important biological pathways involving cytokine-cytokine receptor interaction, transcriptional misregulation in cancer and hematopoietic cell lineage ([Table 3](#pone-0086619-t003){ref-type="table"} and [Fig. 3B](#pone-0086619-g003){ref-type="fig"}). Only one gene in this cluster was found to be related to the acute myeloid leukaemia pathway ([Table 3](#pone-0086619-t003){ref-type="table"} and [Fig. 3B](#pone-0086619-g003){ref-type="fig"}).

### Early up-regulated but later normalized genes (cluster 3) {#s3b3}

This group of genes exhibited significant up-regulation at an early time point in Cy treatment, but the expression was later normalized to the same level as before the start of treatment ([Fig. 2C](#pone-0086619-g002){ref-type="fig"}). This cluster included 33 genes ([Table 2](#pone-0086619-t002){ref-type="table"}). Analysis of biological pathways related to these genes showed that although several pathways are involved ([Table 3](#pone-0086619-t003){ref-type="table"}), only one gene in each pathway is affected by treatment with Cy ([Fig. 3C](#pone-0086619-g003){ref-type="fig"}).

### Moderately up-regulated genes (cluster 4) {#s3b4}

Finally, treatment with Cy resulted in moderate up-regulation of a group of genes, mainly by the end of treatment (6 hr after the second dose; [Fig. 2D](#pone-0086619-g002){ref-type="fig"}). There were 90 genes in this cluster ([Table 2](#pone-0086619-t002){ref-type="table"}) and the biological pathway analysis demonstrated that several pathways including cytokine-cytokine receptor interaction (4 genes), Jak-STAT signalling pathway (2 genes) and TGF-beta signalling pathway (2 genes) are related to this cluster ([Table 3](#pone-0086619-t003){ref-type="table"} and [Fig. 3D](#pone-0086619-g003){ref-type="fig"}).

Disease-related Common Up-regulated Genes {#s3c}
-----------------------------------------

Hierarchical clustering analysis showed that 2 genes, angiopoietin-like-1 (ANGPTL1) and c-JUN proto-oncogene (c-JUN), were considerably up-regulated prior to, during and after treatment with Cy in all tested patients. Further, these results were confirmed by qRTPCR and showed that these two genes were up-regulated in the patients treated with Cy. [Figure 4A](#pone-0086619-g004){ref-type="fig"} shows the results obtained from qRTPCR analysis of ANGPTL1, the gene expression was up-regulated from time 0 e.g. before Cy treatment and continued to be at a high expression level on 6 h after the first dose, 24 h (time before second dose) and at 6 h after the second dose (30 h) compared to control (healthy subjects). As ANGPTL1, and independent of Cy treatment, c-JUN gene expression was also found to be high expressed compared to healthy subjects ([Fig. 4B](#pone-0086619-g004){ref-type="fig"}).

![Effect of cyclophosphamide treatment on ANGPTL1 and c-JUN.\
The relative expression as measured by qRTPCR (normalized to GAPDH) of disease-related up-regulated genes, ANGPTL1 (A) and c-JUN (B), compared to normal subjects. Cy treatment did not affect the up-regulation of ANGPTL1 and c-JUN.](pone.0086619.g004){#pone-0086619-g004}

Discussion {#s4}
==========

This is the first global gene expression profiling study of patients suffering from haematological malignancies, treated with Cy as a conditioning regimen and undergoing HSCT. The data analysis has generated comprehensive knowledge that can be employed in understanding the rationales by which Cy is used as an immunosuppressive/immunoregulatory or conditioning agent.

Our first set of findings that treatment with Cy down-regulated the expression of several genes mapped to immune/autoimmune activation, allograft rejection and GVHD strongly confirm that this alkylating agent is a potent immunosuppressive agent. In this connection, the most noticeable down-regulated genes are CD3, CD28, CTLA4, MHC II, PRF1, GZMB and IL-2R.

CD3 molecule is a complex protein that is expressed as a co-receptor in all mature T lymphocytes and is a subset of NK cells [@pone.0086619-Soudais1]. This co-receptor molecule plays a key role in T cell activation and is therefore a potential target for several drugs, including monoclonal antibodies for the treatment of different autoimmune diseases [@pone.0086619-Chatenoud1], [@pone.0086619-Kaufman1]. In this respect, down-regulation of CD3 gene expression implies that the initial event of T cell activation, which requires the formation of a complex consisting of CD3 and T cell receptor, is impaired upon treatment with Cy.

CD28 and CTLA4 are two surface molecules that play a crucial role in activation and subsequent regulation of cell-mediated immune responses [@pone.0086619-Magistrelli1]. CD28 is constitutively expressed on the surface of T cells and provides a key co-stimulatory signal upon interaction with CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells [@pone.0086619-Waterhouse1]. In contrast, CTLA4 is transiently expressed in activated T cells. CTLA4, by binding to CD80 or CD86, delivers negative signals, which leads to T cell inactivation [@pone.0086619-Waterhouse1]. Our observation that treatment with Cy down-regulated the expression of both CD28 and CTLA4 suggests that this drug exerts dual effects on T cells as it suppresses the early phase of T cell activation as well as prolongs the activity of effector T cells.

MHC II molecules (major histocompatibility complex class II molecules) are the key molecules involved in presenting antigens to CD4+ T cells. These molecules are constitutively expressed in professional (macrophages, dendritic and B cells) and non-professional (thymic epithelial cells) antigen presenting cells [@pone.0086619-Ting1]. By binding to foreign peptides, these molecules provide "signal 1" for activation of CD4+ T cells. Thus, down-regulation of the expression of MHC II in Cy treated patients implies that this drug prevents T cell activation by impairing the process of MHC II mediated antigen presentation. Furthermore, this mechanism of action can also explain the efficacy of Cy in the treatment of autoimmune diseases (e.g. RA and SLE) where antigen presentation and antigen presenting cells (in particular B-cells) play a crucial role.

Due to its effect on autoimmune diseases, cyclophosphamide has recently been used in high doses after HSCT to prevent graft rejection and GVHD [@pone.0086619-Luznik1]. Moreover, HLA matching does not seem to be important if the patient receives post-transplantation Cy, which is a great advantage to patients lacking conventional donors [@pone.0086619-Bashey1], [@pone.0086619-Luznik2].

The PRF1 (perforin-1) gene encodes a cytolytic protein, which is found in cytotoxic T cells and NK cells. PRF1 shares similarities in both structure and function with complement component 9 (C9) [@pone.0086619-Rosado1]. Like BRF1, GZMB (granzyme B) is a protease expressed by cytotoxic T lymphocytes and NK cells and induces apoptosis on target cells [@pone.0086619-Trapani1]. It has been demonstrated that granzyme can access its target cells through pores formed by perforin [@pone.0086619-Lopez1]. Our observation that the expression of BRF1 and GZMB genes are down-regulated upon treatment with Cy strongly suggests that cytotoxic activity of the immune cells mainly mediated by CD8+ T and NK cells is also lessened by Cy.

IL-2R (Interleukin-2 receptor) is expressed on the activated T cells as well as regulatory T (T~reg~) cells (also known as suppressor T cells). Upon binding to IL-2, IL-2R promotes cell cycle progression through phase G1 of the cell cycle, which leads to the onset of DNA synthesis and replication [@pone.0086619-Martino1]. Therefore, down-regulation of IL-2R gene expression in Cy treated patients may prevent alloreactivity against donor hematopoietic stem cells. Furthermore, this reduction in IL-2R expression might also attenuate the number of T~reg~ cells, which are known to play an unfavourable role in malignancies [@pone.0086619-Cao1], [@pone.0086619-Matias1]. In line with this statement, it has been shown that Cy can suppress T~reg~ cells and allow more effective induction of antitumor immune responses [@pone.0086619-Le1].

In addition to the genes related to the immune system, our findings also demonstrated that treatment with Cy down-regulates the expression of several genes (e.g., Ras, LMO2, MCM4 and MCM7) that are related to cancer development and cell cycle progression. For instance, Ras (rat sarcoma) oncoproteins are known to be responsible for signal transmission inside the cells and for participating in cell growth, differentiation and survival [@pone.0086619-Wennerberg1]. Oncogenic mutations in Ras genes have been detected in several human cancers [@pone.0086619-Goodsell1], [@pone.0086619-Bos1].

The LMO2 (LIM domain only 2) gene encodes a cysteine-rich, two protein structural domain that plays an important role in hematopoietic development; moreover, its ectopic expression in T cells leads to the onset of acute lymphoblastic leukaemia (ALL) [@pone.0086619-ElOmari1]. In mice, LMO2 induced precancerous stem cells and even initiated leukaemia (T-ALL) by inducing thymocyte self-renewal [@pone.0086619-McCormack1], [@pone.0086619-McCormack2].

Finally, minichromosome maintenance proteins (MCM) 4 and 7 are known to be essential for the initiation of genomic replication [@pone.0086619-Kearsey1] and their down-regulation during Cy treatment confirms the ability of this drug to reduce cancer size by slowing cell replication. MCM4 and MCM7 were found in both DNA replication and cell cycle pathways. Thus, Cy induced down regulation in Ras, LMO2, MCM4 and MCM7 genes might shed light on the mechanisms underlying the anti-cancer effects of Cy.

Our findings in this study have also demonstrated that in addition to the down-regulated genes, several genes are up-regulated during treatment with Cy. Most of these genes are immune-related receptor genes, e.g. IL1R2 (interleukin 1 receptor, type II or CD121b), IL18R1 (interleukin-18 receptor 1 or CDw218a) and FLT3 (Fms-like tyrosine kinase 3, or CD135). IL1R2 is a protein expressed on B cells, monocytes and neutrophils and functions as a molecular decoy that sequesters IL-1β and blocks the initiation of downstream signalling, thereby preventing inflammation [@pone.0086619-Mantovani1]. Moschella *et al*. have reported that IL-1β was increased to reach maximum concentration at day 3 after Cy administration which is in good agreement with our finding [@pone.0086619-Moschella1]. On the other hand, IL18R1 is a cytokine receptor that specifically binds interleukin 18 (IL18) and is essential for IL18 mediated signal transduction. IFN-α as well as IL12 are reported to induce the expression of this receptor in NK and T cells. Interestingly, IL18R1 and IL1R2 genes along with three other members of the interleukin 1 receptor family, including IL1R1, ILRL2 (IL-1Rrp2), and IL1RL1 (T1/ST2) form a gene cluster on chromosome 2q [@pone.0086619-Dale1]. Thus, Cy induced increase in expression of IL1R2 and IL18R1 suggests that cytokine receptor genes located on chromosome 2q are susceptible to Cy. In a recent publication, Moscella *et al.* have reported that Cy has activated IFN-α signature and IFN-α --induced proinflammatory mediators. Moreover, Cy also has induced expansion and activation of IL18R1 and other receptors [@pone.0086619-Moschella2]. These results confirm our finding; however, further studies are required to confirm mechanisms underlying this hypothesis.

FLT3 is a protein expressed on the surface of many hematopoietic progenitor cells and plays an important role in the development of B and T progenitor cells [@pone.0086619-Rosnet1]. However, it remains to be elucidated if increased expression of FLT3 implies that treatment with Cy might lead either directly or indirectly to mobilization of hematopoietic progenitor cells to the periphery.

Our results showed a significant increase (confirmed by qRTPCR) in the expression of angiopoietin-related protein 1 (ANGPTL1) and c-JUN proto-oncogene (c-JUN) genes in all patients. The high expression was independent of Cy treatment. These two genes are known to play an important role in cancer, i.e. ANGPTL1, which is a member of the vascular endothelial growth factor family, was reported to mediate a defence mechanism against cancer growth and metastasis. In this respect, Kuo *et al.* reported the inverse correlation between the expression of ANGPTL1 and cancer invasion and lymph node metastasis in lung cancer patients and experimental cancer models [@pone.0086619-Kuo1].

Overexpression of c-JUN has been shown in several human cancer types such as non-small cell lung cancer, breast cancer, colon cancer and lymphomas [@pone.0086619-Szabo1]--[@pone.0086619-Zhang2]. Moreover, c-JUN was reported to be associated with proliferation and angiogenesis in invasive breast cancer [@pone.0086619-Vleugel1]. Jiao et al. have reported that c-JUN induced epithelial cellular invasion in breast cancer [@pone.0086619-Jiao1]. Cancer cells are rapidly dividing and c-JUN is important for progression through the G1 phase of the cell cycle [@pone.0086619-Wisdom1]. c-JUN antagonizes P53 expression which is a cell cycle arrest inducer [@pone.0086619-Schreiber1]. Moreover, c-JUN is an apoptosis down-regulator, which is important for cancer cell survival [@pone.0086619-Wisdom1]. c-JUN was reported to promotes BCR-ABL induced lymphoid leukemia [@pone.0086619-Kollmann1]. Furthermore, the expression of c-JUN was reported to be enhanced in chemotherapy resistant tumors [@pone.0086619-Ritke1]--[@pone.0086619-Zhou1].

In the present investigation, the high expression of ANGPTL1 and c-JUN genes was observed throughout the treatment with no effect of Cy therapy on these genes. Thus, based on our findings and the reported studies, we propose that these genes might be considered as potential markers for therapeutic efficacy connected to haematological malignancies. In addition, we strongly believe that targeting the gene expression of c-JUN might have therapeutic potential for these diseases [@pone.0086619-Gurzov1], [@pone.0086619-Xia1].

In conclusion, our results in the present study provide significant information about the alterations in gene expression caused by Cy treatment. We demonstrate here that Cy induces both down- and up-regulation in genes, mainly belonging to the immune system. This knowledge can be expanded further to evaluate which Cy metabolites are responsible for these effects and how Cy can be employed to target specific immune function in order to optimize Cy treatment and/or to minimize the treatment related toxicity and hence enhance HSCT clinical outcome. Our findings also show Cy independent over expression of some genes that have been reported in solid tumours. These may suggest that these genes may be used as a target treatment for haematological malignancies. However, several studies are warranted.
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